Johnson & Johnson (XSWX:JNJ) Other Long-Term Liabilities: CHF8,074 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:JNJ Johnson & Johnson XSWX:JNJ
24 GF Score
Price CHF207.40
GF Value CHF154.96
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Other Long-Term Liabilities?

Johnson & Johnson XSWX:JNJ +0.39% 24 Other Long-Term Liabilities is CHF8,074 Mil as of Jun. 2026. GuruFocus rates XSWX:JNJ with a GF Score™ of 24/100 and a GF Value™ of CHF154.96 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's other long-term liabilities for the quarter that ended in Jun. 2026 was CHF8,074 Mil.

Johnson & Johnson's quarterly other long-term liabilities increased from Dec. 2025 (CHF7,864 Mil) to Mar. 2026 (CHF8,037 Mil) and increased from Mar. 2026 (CHF8,037 Mil) to Jun. 2026 (CHF8,074 Mil).

Johnson & Johnson's annual other long-term liabilities increased from Dec. 2023 (CHF11,587 Mil) to Dec. 2024 (CHF15,647 Mil) but then declined from Dec. 2024 (CHF15,647 Mil) to Dec. 2025 (CHF7,864 Mil).


Johnson & Johnson Other Long-Term Liabilities Related Terms


Johnson & Johnson Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Other Long-Term Liabilities Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,841.81 12,154.58 11,586.59 15,646.69 7,863.81

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,345.87 7,902.09 7,863.81 8,036.76 8,073.73
XSWX:JNJ
24GF Score
Johnson & Johnson XSWX:JNJ
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF8,074 Mil mean?
Johnson & Johnson (XSWX:JNJ) has a Other Long-Term Liabilities of CHF8,074 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Other Long-Term Liabilities too high?
Johnson & Johnson's current Other Long-Term Liabilities is CHF8,074 Mil. Overall, Johnson & Johnson has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Other Long-Term Liabilities compare to ABBV and MRK?
Johnson & Johnson's Other Long-Term Liabilities of CHF8,074 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Other Long-Term Liabilities is CHF8,074 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (XSWX:JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF154.96, compared to a current price of CHF207.40 — trading 33.8% above its estimated fair value. The current Other Long-Term Liabilities is CHF8,074 Mil. Johnson & Johnson's overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Johnson & Johnson (XSWX:JNJ), the current Other Long-Term Liabilities is CHF8,074 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (XSWX:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of CHF207.40 is trading 33.8% above its estimated GF Value™ of CHF154.96. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for XSWX:JNJ:

  • Other Long-Term Liabilities: CHF8,074 Mil
  • GF Value™: CHF154.96 vs. price of CHF207.40 (33.8% above fair value)
  • GF Score™: 24/100 with 7 warning signs

No single metric tells the full story. See the XSWX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
24GF Score

Get the complete analysis for XSWX:JNJ

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF207.40
Price
CHF154.96
GF Value